IMMUTEP LTD-SP ADR

IMMPNASDAQ

Earnings Aug 29 · PostUS Equity

$0.38▼ $0.01 (−2.59%)

🌙 After hours$0.38▲ 0.00%Regular close · extended-hours price shown

1h—

24h▼ 2.6%

7d▲ 3.5%

14d▼ 0.7%

30d▼ 12.3%

1y▼ 77.5%

🏦Market Cap

$565M

Small Cap

📈Revenue Growth (YoY)

+7574.0%

High Growth

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

17.1x

Expensive

Otter Score

Weak

Trading Snapshot

Day Range: $0.38 – $0.39
52-Week Range: —
Volume: $3.01B
Avg Volume: $2.09B
Shares Outstanding: 1.47B
Next Earnings: Oct 4, 2026

Fundamentals Snapshot

Annual Revenue: $5M
Last Q Revenue: $6M
P/E Ratio: —
P/S Ratio: 17.1x
EPS (TTM): —
Dividend Yield: —

Why Investors Own IMMP

✓High-growth profile — revenue up +43.9% YoY with expanding US Equity exposure.
✓Healthy economics — 41% gross margin and 14% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$5M▲ +43.8% YoY

Gross Margin (TTM)

40.8%▲ +4.0% YoY

Operating Income (TTM)

$1M▲ +43.8% YoY

Free Cash Flow (TTM)

$690,997▲ +43.8% YoY

About IMMUTEP LTD-SP ADR

Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); INSIGHT-005 which is in phase I for metastatic urothelial carcinoma; TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. It also develops INSIGHT-003, which is in phase I trial 1L non squamous NSCL; INSIGHT-005 that is in phase I to treat metastatic urothelial cancer; IMP761, which is in phase I Trial to treat autoimmune disease; IMP731 for oncology and autoimmune diseases; and LAG525. Immutep has collaboration with Merck & Co., Inc., EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia.

🦦